Trials / Completed
CompletedNCT04321499
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
Establishing a Non-invasive Diagnostic Biomarker Test for Early Diagnosis of Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (actual)
- Sponsor
- University Hospital, Essen · Academic / Other
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. SHOX2 and PTGER4 will be analyzed via PCR.
Detailed description
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | lung cancer | PCR for SHOX2 and PTGER4 |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2020-03-25
- Last updated
- 2020-03-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04321499. Inclusion in this directory is not an endorsement.